Alnylam Pharmaceuticals, Inc. (ALNY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2025)
ALNY's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ALNY Revenue Analysis (2014–2025)
As of February 28, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) generated trailing twelve-month (TTM) revenue of $3.71 billion, reflecting explosive growth of +84.9% year-over-year. The most recent quarter (Q4 2025) recorded $1.10 billion in revenue, down 12.2% sequentially.
Looking at the longer-term picture, ALNY's 5-year compound annual growth rate (CAGR) stands at +49.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $3.71 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows ALNY's business is primarily driven by GIVLAARI (64%), and ONPATTRO (36%). With over half of revenue concentrated in GIVLAARI, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including IONS (+33.8% YoY), ARWR (+4081.8% YoY), and CRSP (-81.7% YoY), ALNY has underperformed the peer group in terms of revenue growth. Compare ALNY vs IONS →
Peer Comparison
Compare ALNY's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALNYCurrent | $3.7B | +84.9% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% | |
| WVE | $108M | +103.7% | +46.6% | -101.9% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.71B | +65.2% | $3.04B | 81.8% | $501.6M | 13.5% |
| 2024 | $2.25B | +23.0% | $1.92B | 85.6% | $-176,885,000 | -7.9% |
| 2023 | $1.83B | +76.2% | $1.52B | 83.0% | $-282,175,000 | -15.4% |
| 2022 | $1.04B | +22.9% | $868.6M | 83.7% | $-785,072,000 | -75.7% |
| 2021 | $844.3M | +71.3% | $704.1M | 83.4% | $-708,652,000 | -83.9% |
| 2020 | $492.9M | +124.3% | $414.8M | 84.2% | $-828,438,000 | -168.1% |
| 2019 | $219.8M | +193.4% | $194.7M | 88.6% | $-939,431,000 | -427.5% |
| 2018 | $74.9M | -16.7% | $73.1M | 97.6% | $-814,673,000 | -1087.6% |
| 2017 | $89.9M | +90.7% | $76.5M | 85.1% | $-500,088,000 | -556.2% |
| 2016 | $47.2M | +14.8% | $47.2M | 100.0% | $-424,587,000 | -900.3% |
See ALNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALNY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ALNY vs AGIO
See how ALNY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ALNY's revenue growth accelerating or slowing?
ALNY revenue is accelerating at +84.9% year-over-year, exceeding the 5-year CAGR of +49.8%. TTM revenue reached $3.7B. Growth momentum has increased versus prior periods.
What is ALNY's long-term revenue growth rate?
Alnylam Pharmaceuticals, Inc.'s 5-year revenue CAGR of +49.8% reflects the sustained expansion pattern. Current YoY growth of +84.9% is above this long-term average.
How is ALNY's revenue distributed by segment?
ALNY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.